Topical berberine gelatin 5 mg/g,
does it really help with Reduction of pain from minor recurrent aphthous ulcers?
research showsGrade C with 46 points. In an 84-completer double-blind trial, pain scores were lower with 5-mg/g gelatin applied four times daily for five days than with vehicle (P<.05), but no exact between-group VAS difference, 95% CI, registry, or independent replication was verified.
ads claimDo not expand this to cure, recurrence prevention, infection treatment, or oral-systemic use.
Useful facts when choosing a product
- This verdict applies only to the displayed formulation, route, dose, duration, population, endpoint, and comparator.
- Berberine hydrochloride, botanical extracts, combination formulas, dihydroberberine, other derivatives, and topical products are not interchangeable.
- Caution. No obvious adverse effects were reported in this short 84-person trial, but local irritation, allergy, swallowed exposure, and pregnancy/lactation safety remain uncertain.
Chamgap Semantic Classification Code
Permanent code issued
S.berberine-gelatin.topical-oral.aphthous-ulcer-pain.reduce.vehicleSupplements and nutraceuticals > Berberine gelatin > Topical oral > Recurrent aphthous-ulcer pain > Reduction claim > Vehicle gelatin
Bound to pain with 5 mg/g four times daily for five days; ulcer size, erythema, exudation, recurrence, and oral berberine are separate. The code identifies the intervention and claim; it never contains the evidence grade, score, or safety result.
Exact Claim Classification
These independent facets prevent evidence from different forms, routes, populations, effects, and comparators from being mixed.
| Intervention class | S · Supplement or nutraceutical |
|---|---|
| Canonical ingredient or intervention | Berberine gelatin |
| Source or part used | Purified berberine; source plant unverified |
| Formulation or processing | Gelatin containing berberine 5 mg/g |
| Route | Topical application to oral ulcers |
| Dose | Four times daily |
| Duration | Five days; assessed on days 1, 2, 4, and 6 |
| Population | Adults with minor recurrent aphthous stomatitis |
| Effect or condition | Reduced ulcer pain |
| Primary endpoint | Pain VAS or score across assessment days |
| Comparator | Vehicle gelatin without berberine |
| Duplicate-detection key | Berberine gelatin|Gelatin containing berberine 5 mg/g|Topical application to oral ulcers|Adults with minor recurrent aphthous stomatitis|Reduced ulcer pain|Five days; assessed on days 1, 2, 4, and 6 |
What the research actually shows
The PMID 23246229 record and abstract were checked; oral berberine, ulcer size, and healing duration were excluded.
Why this is classified as C (46)
Axes are P/R1/I1/EX/B2/CX. There are no counted strengths; fewer than 200 participants, under 12 weeks, and no precise effect yield C/46.
Counterpoint. Placebo control, double masking, and a favorable direction are supportive, but this remains one 84-person five-day trial.
Rejudgment record. Independent Codex cross-check — One formulation, route, population, claim, principal endpoint, and comparator
| Endpoint | P | Patient-reported treatment goal - the symptom is the goal |
| Replication | R1 | Single confirmatory trial |
| Independence | I1 | Mixed funding sources |
| Effect size | EX | The clinical size of the effect could not be judged |
| Precision | CX | No pooled confidence interval could be confirmed |
The scoring table and the verdict agree (C).
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Effects of berberine gelatin on recurrent aphthous stomatitis: a randomized, placebo-controlled, double-blind trial in a Chinese cohort | Design, allocation, masking, endpoint hierarchy, and analysis set were independently checked. | 84 | Funding, product support, employee authorship, and conflicts were assessed separately. | The principal endpoint contract is preserved; other outcomes remain separate. | Verified estimates are preserved; missing confidence intervals were not invented. | Evidence weight reflects directness, formulation match, hierarchy, and reporting limitations. |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-09-08).
Final verification and publication gate: Codex · Verification cutoff: 2026-09-08 · Corrections: none
Cite this verdict
[Chamgap] Berberine Gelatin for Aphthous-Ulcer Pain—A Positive Five-Day Placebo Trial Without an Effect Size or 95% CI — Evidence Grade C·46. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/immunity/topical-berberine-gelatin-recurrent-aphthous-ulcer-pain/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.